Leap Therapeutics Inc
NASDAQ:LPTX
Intrinsic Value
Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of LPTX.
Leap Therapeutics Inc's market capitalization is 81m USD.
LPTX stock price is 3.17 USD.
LPTX.
LPTX. Open DCF Valuation
LPTX. Open Relative Valuation
LPTX has upside potential of 278% compared to the average analyst price target.
Open Wall St Estimates
LPTX's ROE (Return on Equity) has significantly decreased in the last 3 years from -104% to -137%, and is approaching profitability.
LPTX's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from 2 161% to 3 425%.
LPTX has negative Operating Income for the last twelve months.
LPTX has negative Net Income for the last twelve months.
LPTX's ROE (Return on Equity) for the past 12 months is negative and is equal to -137%.
LPTX's ROIC (Return on Invested Capital) for the past 12 months is very high and is equal to 3 425%.
LPTX has negative Free Cash Flow for the last twelve months.
LPTX has negative three-year average ROE (Return on Equity): -88%. The company is not efficient at transforming stockholders' equity into net income.
LPTX has very high three-year average ROIC (Return on Invested Capital): 3 133%. The company is very efficient at using invested capital to generate operating income.
LPTX's short-term assets (72m USD) exceed its short-term liabilties (13m USD).
LPTX's long-term assets (73m USD) exceed its long-term liabilties (13m USD).
LPTX's D/E (Debt to Equity) is very low and is equal to 0.
LPTX's Altman Z-Score is very low and is equal to -6.81.
Fundamental Analysis
Leap Therapeutics Inc
Balance Sheet Decomposition
Leap Therapeutics Inc
| Current Assets | 71.6m |
| Cash & Short-Term Investments | 70.6m |
| Receivables | 771k |
| Other Current Assets | 183k |
| Non-Current Assets | 1.2m |
| PP&E | 262k |
| Other Non-Current Assets | 966k |
| Current Liabilities | 12.7m |
| Accounts Payable | 6.5m |
| Accrued Liabilities | 6.2m |
Earnings Waterfall
Leap Therapeutics Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-87m
USD
|
|
Operating Income
|
-87m
USD
|
|
Other Expenses
|
5.6m
USD
|
|
Net Income
|
-81.4m
USD
|
Free Cash Flow Analysis
Leap Therapeutics Inc
LPTX Profitability Score
Profitability Due Diligence
Leap Therapeutics Inc's profitability score is 39/100. The higher the profitability score, the more profitable the company is.
Score
Leap Therapeutics Inc's profitability score is 39/100. The higher the profitability score, the more profitable the company is.
LPTX Solvency Score
Solvency Due Diligence
Leap Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Leap Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LPTX Price Targets Summary
Leap Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
LPTX
is 11.99 USD
with a low forecast of 7.07 USD and a high forecast of 16.8 USD.
Ownership
LPTX Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
LPTX Price
Leap Therapeutics Inc
| Average Annual Return | 8.63% |
| Standard Deviation of Annual Returns | 87.1% |
| Max Drawdown | -97% |
| Market Capitalization | 81m USD |
| Shares Outstanding | 25 603 500 |
| Percentage of Shares Shorted | 4.58% |
Company Profile
Leap Therapeutics Inc
Country
Industry
Market Cap
Dividend Yield
Description
Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 36 full-time employees. The company went IPO on 2017-01-24. The firm is focused on developing therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. The Company’s clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. When DKN-01 binds to DKK1, an anti-tumor effect can be generated. DKK1 is a cell secreted protein that research has found its role in embryonic development. DKN-01 is an affinity, neutralizing monoclonal antibody targeting DKK1. DKN-01 reduces free DKK1 levels and has demonstrated an anti-tumor effect in preclinical models.
You don't have any saved screeners yet
